KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.19
+0.63 (0.30%)
AAPL  274.12
+1.99 (0.73%)
AMD  212.20
-1.64 (-0.77%)
BAC  51.67
+1.27 (2.51%)
GOOG  310.50
-0.42 (-0.14%)
META  649.45
+10.15 (1.59%)
MSFT  398.67
+9.67 (2.49%)
NVDA  196.69
+3.84 (1.99%)
ORCL  149.36
+3.22 (2.20%)
TSLA  414.50
+5.12 (1.25%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.